Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 5 (2008), Issue 7 (July)

1. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents.
   Clin Cancer Res, 14(13): 4326-35. [Abstract] [Full-text]
2. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.
   Anticancer Drugs, 19(7): 753-9. [Abstract] [Full-text]
3. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
   Anticancer Drugs, 19(7): 689-96. [Abstract] [Full-text]
4. Flow Cytometric FRET Analysis of erbB Receptor Interaction on a Cell-by-Cell Basis.
   Ann N Y Acad Sci, 1130: 280-6. [Abstract] [Full-text]
5. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
   Drug Resist Updat, 11(3): 99-109. [Abstract] [Full-text]
6. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
   J Clin Oncol, 26(20): 3317-23. [Abstract] [Full-text]
7. Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls.
   BMC Med Imaging, 8: 11. [Abstract] [Full-text]
8. HER-2 status in gastrointestinal stromal tumor.
   Ann Diagn Pathol, 12(4): 283-5. [Abstract] [Full-text]
9. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.
   Int J Gynaecol Obstet, 102(2): 128-31. [Abstract] [Full-text]
10. Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab.
    Pharmacoepidemiol Drug Saf, 17(7): 714-21. [Abstract] [Full-text]
11. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
    Cancer Treat Rev, 34(5): 391-406. [Abstract] [Full-text]
12. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.
    Clin Cancer Res, 14(14): 4564-71. [Abstract] [Full-text]
13. Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.
    Bioconjug Chem, 19(7): 1439-47. [Abstract] [Full-text]
14. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Cancer Res, 68(14): 5878-87. [Abstract] [Full-text]
15. Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma.
    Acta Histochem Cytochem, 41(3): 59-64. [Abstract] [Full-text]
16. Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.
    Mol Cancer Ther, 7(7): 1900-8. [Abstract] [Full-text]
17. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Breast Cancer Res Treat, 111(2): 241-50. [Abstract] [Full-text]
18. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides.
    Proteomics, 8(14): 2858-71. [Abstract] [Full-text]

© 2004-2010 Herceptin Research Today. All Rights Reserved.